NEXT Oncology, an Avacare business shared on LinkedIn:
“In 2022, NEXT Oncology treated one of the first patients with daraxonrasib, a potentially promising treatment for pancreatic cancer.
Our sites went on to enroll more than 100 patients across the Phase 1 program for Revolution Medicines and subsequent combination cohorts.
Now, Rasonque (daraxonrasib) is FDA approved for previously treated metastatic pancreatic cancer.
This is why early drug development matters.
About ‘All Together We Can’ Campaign
The ‘All Together We Can‘ initiative is a $250 million campaign launched by the Pancreatic Cancer Action Network (PanCAN) with the goal of making survival the expectation rather than the exception for pancreatic cancer patients. Timed around Pancreatic Cancer Awareness Month in November, the campaign focuses on catching the disease earlier, connecting patients to optimal care from day one, and accelerating scientific breakthroughs.
PanCAN emphasizes that pancreatic cancer research has reached a major turning point, highlighted by a momentous FDA approval of a treatment targeting the mutations that drive over 90% of pancreatic cancer cases, alongside the largest pipeline of investigational drugs in the field’s history.
PanCAN’s broader work has achieved the following milestones:
- 560,000+: Patients, caregivers, and healthcare professionals supported through PanCAN Patient Services.
- $259 Million: Total funds invested in pancreatic cancer research to fuel new discoveries.
- 3x Survival: Patients today are more than three times as likely to survive past five years compared to when PanCAN first began its work.
You can also read: Phase 3 RASolute 309 Trial Begins: RASONQUE Plus Zoldonrasib in First-Line RAS G12D PDAC
